- OSPN Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
SC TO-I/A Filing
OneSpan (OSPN) SC TO-I/AIssuer tender offer statement (amended)
Filed: 5 Dec 23, 4:59pm
UNITED STATES |
AMENDMENT NO. 2 TO SCHEDULE TO |
OneSpan Inc. |
Common Stock, par value $0.001 per share |
OneSpan Inc. General Counsel, Chief Compliance Officer and Corporate Secretary 1 Marina Park Drive, Unit 1410 Boston, Massachusetts 02210 (312) 766-4001 (Name, address and telephone number of person authorized to receive |
Copy to:
Albert Lung, Esq. Morgan, Lewis & Bockius LLP 1400 Page Mill Road Palo Alto, CA 94304-1124 (650) 843-7263 |
☐ | Check the box if filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
☐ | third-party tender offer subject to Rule 14d-1. | |
☒ | issuer tender offer subject to Rule 13e-4. | |
☐ | going-private transaction subject to Rule 13e-3. | |
☐ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
AMENDMENT NO. 2 TO SCHEDULE TO
This Amendment No. 2 (this “Amendment”) to Tender Offer Statement on Schedule TO amends and supplements the Tender Offer Statement on Schedule TO originally filed by OneSpan, Inc., a Delaware corporation (the “Company,” “our,” “we,” or “us”), on November 13, 2023 (the “Original Schedule TO”), as amended on December 1, 2023 (the “Amended Schedule TO” and as may be further supplemented or amended from time to time, the “Tender Offer Statement”) in connection with the Offer (as defined below) by the Company to purchase up to $20 million in value of shares of its Common Stock, par value $0.001 per share (the “Shares”), at a price not greater than $11.00 nor less than $9.50 per Share, to the seller in cash, less any applicable withholding taxes and without interest.
The terms and conditions of the Offer are described in the Offer to Purchase, dated November 13, 2023, as amended on December 1, 2023 (as so amended, the “Amended Offer to Purchase”) and as further amended on December 5, 2023 (the “Further Amended Offer to Purchase”), a copy of which is filed herewith as Exhibit (a)(1)(I), and the related Letter of Transmittal, dated November 13, 2023 (the “Letter of Transmittal,” which, together with the Amended Offer to Purchase, as each may be amended or supplemented from time to time, with respect to the Shares, collectively constitute the “Offer”).
This Amendment and the exhibits hereto should otherwise be read in conjunction with the Original Schedule TO and the Amended Schedule TO. The Tender Offer Statement is intended to satisfy the reporting requirements of Rule 13e-4(c)(2) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The information contained in the Further Amended Offer to Purchase and the Letter of Transmittal, respectively, as each may be amended or supplemented from time to time, is hereby incorporated by reference in response to certain items of this Amendment.
This Amendment is being filed to amend and supplement the Original Schedule TO and the Amended Schedule TO for the purpose of amending and restating the first sentence of the fourth paragraph on page iii of the Amended Offer to Purchase and identical sentences on pages 9 and 14 of the Amended Offer to Purchase and related disclosures in the Letter to Clients, the further amended version of which is filed herewith as Exhibit (a)(1)(J).
“We are not soliciting any Shares in the Offer in any jurisdiction where it would be illegal to do so, provided that we will comply with the requirements of Rule 13e-4(f)(8) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).”
In addition, the Amended Schedule TO is hereby amended and supplemented as follows:
Items 1 through 9 and Item 11
Items 1 through 9 and Item 11 of the Amended Schedule TO are hereby amended and supplemented as set forth below:
“All descriptions and references in respect of the ‘Amended Offer to Purchase’ in the Amended Schedule TO are hereby amended to refer to the ‘Further Amended Offer to Purchase.’ Accordingly, all references in the Amended Schedule TO to the ‘Amended Offer to Purchase’ are hereby amended and replaced with ‘Further Amended Offer to Purchase.’”
Except as amended hereby to the extent specifically provided herein, all terms of the Offer and all other disclosures set forth in the Original Schedule TO, the Amended Schedule TO and the exhibits thereto remain unchanged and are hereby expressly incorporated into this Amendment by reference. Capitalized terms used and not otherwise defined in this Amendment shall have the meanings assigned to such terms in the Original Schedule TO and the Amended Offer to Purchase.
Item 12. Exhibits
Item 12 of the Amended Schedule TO is hereby amended and restated in its entirety as set forth below:
“Item 12. Exhibits.
Exhibit No | Description |
(a)(1)(A)* | Offer to Purchase, dated November 13, 2023. |
(a)(1)(B)* | Letter of Transmittal. |
* Previously filed on November 13, 2023 as an exhibit to the Original Schedule TO.
** Previously filed on December 1, 2023 as an exhibit to the Amended Schedule TO.
***Filed herewith.”
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
OneSpan Inc. | ||||
By: | /s/ Lara Mataac | |||
Lara Mataac | ||||
General Counsel, Chief Compliance Officer and Corporate Secretary | ||||
Date: | December 5, 2023 | |||